KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2023 - 2025)

Alnylam Pharmaceuticals' Long-Term Deferred Tax history spans 7 years, with the latest figure at $126.0 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 7.8% year-over-year to $126.0 million; the TTM value through Dec 2025 reached $126.0 million, up 7.8%, while the annual FY2025 figure was $126.0 million, 7.8% up from the prior year.
  • Long-Term Deferred Tax reached $126.0 million in Q4 2025 per ALNY's latest filing, up from $98.6 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $126.0 million in Q4 2025 to a low of $10.1 million in Q4 2023.
  • Average Long-Term Deferred Tax over 3 years is $93.8 million, with a median of $105.8 million recorded in 2025.
  • Peak YoY movement for Long-Term Deferred Tax: surged 1056.94% in 2024, then increased 7.8% in 2025.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $10.1 million in 2023, then soared by 1056.94% to $116.9 million in 2024, then increased by 7.8% to $126.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Long-Term Deferred Tax are $126.0 million (Q4 2025), $98.6 million (Q3 2025), and $104.4 million (Q2 2025).